BioCentury
ARTICLE | Finance

Playing the CVR

Genzyme's $14 CVR from sanofi worth about $2; what could change it

February 21, 2011 8:00 AM UTC

Much of the time that Genzyme Corp. and sanofi-aventis Group spent bargaining over Genzyme's acquisition was devoted to the value of Lemtrada alemtuzumab in multiple sclerosis. They finally agreed on a $14 contingent value right, $13 of which is devoted to Lemtrada. Now the market will get its say.

The first number it's come up with is $2...